deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 2-arm NCT04209686

Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma

Phase 2 Study of Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma

Sponsor: Merck Sharp & Dohme LLC

Conditions Advanced Gastric Adenocarcinoma
Interventions Olaparib Paclitaxel Pembrolizumab
Updated 21 times since 2020 Last updated: Dec 1, 2025 Started: Jul 31, 2020 Primary completion: Sep 1, 2028 Completion: Sep 1, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04209686, this PHASE2 trial focuses on Advanced Gastric Adenocarcinoma and remains ongoing. Sponsored by Merck Sharp & Dohme LLC, it has been updated 21 times since 2020, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~May 2020 · 2 months · monthly snapshot~May 2020 – ~Jul 2020 · 2 months · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~Apr 2022 · 7 months · monthly snapshot~Apr 2022 – ~Jun 2022 · 2 months · monthly snapshot~Jun 2022 – ~Apr 2023 · 10 months · monthly snapshot~Apr 2023 – ~Sep 2023 · 5 months · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Apr 2024 · 6 months · monthly snapshot~Apr 2024 – ~Jun 2024 · 2 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jun 2025 · 9 months · monthly snapshot~Jun 2025 – ~Jan 2026 · 7 months · monthly snapshot~Jan 2026 – present · 3 months · monthly snapshot

Change History

21 versions recorded

  1. Jan 2026 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Jun 2025 — Jan 2026 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Sep 2024 — Jun 2025 [monthly]

    Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  5. Jun 2024 — Jul 2024 [monthly]

    Recruiting PHASE2

▶ Show 16 earlier versions

  1. Apr 2024 — Jun 2024 [monthly]

    Recruiting PHASE2

  2. Oct 2023 — Apr 2024 [monthly]

    Recruiting PHASE2

  3. Sep 2023 — Oct 2023 [monthly]

    Recruiting PHASE2

  4. Apr 2023 — Sep 2023 [monthly]

    Recruiting PHASE2

  5. Jun 2022 — Apr 2023 [monthly]

    Recruiting PHASE2

  6. Apr 2022 — Jun 2022 [monthly]

    Recruiting PHASE2

  7. Sep 2021 — Apr 2022 [monthly]

    Recruiting PHASE2

  8. May 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  9. Apr 2021 — May 2021 [monthly]

    Recruiting PHASE2

  10. Jan 2021 — Apr 2021 [monthly]

    Recruiting PHASE2

  11. Aug 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  12. Jul 2020 — Aug 2020 [monthly]

    Not Yet Recruiting PHASE2

  13. May 2020 — Jul 2020 [monthly]

    Not Yet Recruiting PHASE2

  14. Mar 2020 — May 2020 [monthly]

    Not Yet Recruiting PHASE2

  15. Feb 2020 — Mar 2020 [monthly]

    Not Yet Recruiting PHASE2

  16. Jan 2020 — Feb 2020 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Merck Sharp & Dohme LLC
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Data source: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations